Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans
- 1 October 1990
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 39 (10) , 1251-1256
- https://doi.org/10.2337/diabetes.39.10.1251
Abstract
Insulinlike growth factor binding protein 1 (IGFBP-1) has been shown to modulate the metabolic and mitogenic actions of the growth hormone (GH)- dependent peptide insulinlike growth factor I. Previous studies showed that levels of IGFBP-1 are regulated by insulin. The relative role of GH in the regulation of IGFBP-1 levels is less well defined and was examined in our study with a contiguous two-part protocol. Overnight (part A) and pre- and post-morning meal (part B) blood samples were obtained from eight healthy adults during a constant infusion of saline (SAL) or 4 μg · kg−1 · min−1 GH. Five of eight subjects were restudied with glucose (GLUC) infused during part B (SAL + GLUC) to match glucose and insulin to levels observed during GH infusion. During SAL infusion, IGFBP-1 levels measured by specific radioimmunoassay showed a marked immediate decline after the evening meal in part A, with a subsequent nocturnal rise of 2.4- to 17.3-fold. GH infusion resulted in a similar meal-induced fall in IGFBP-1 levels but led to a delayed nocturnal rise in IGFBP-1, which was associated with elevated postprandial insulin concentrations. During part B, changes in plasma IGFBP-1 levels showed a similar pattern, with a delayed postprandial increase observed during both GH and SAL + GLUC infusions. The half-life of IGFBP-1 disappearance was calculated at ∼2 h for all three infusion groups. Comparison of venous and arterialized blood samples showed no consistent pattern of difference, arguing against peripheral tissue clearance or compartmentalization as the mechanism for the rapid rise and fall in IGFBP-1 levels. Our studies, the first to measure GH, insulin, and glucose in concurrent sampling and under controlled physiological conditions, support previous investigations suggesting that insulin (not GH or glucose) is the primary regulator of plasma IGFBP-1 levels. Furthermore, we postulate that the observed fluctuations in plasma levels are caused by a direct insulin effect on hepatic IGFBP-1 production.This publication has 19 references indexed in Scilit:
- Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosaActa Endocrinologica, 1988
- Insulin-Like Growth Factor (IGF) Binding Protein from Human Decidua Inhibits the Binding and Biological Action of IGF-I in Cultured Choriocarcinoma Cells**Endocrinology, 1988
- Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II ReceptorsMolecular Endocrinology, 1988
- Insulin Regulates the Serum Levels of Low Molecular Weight Insulin-Like Growth Factor-Binding Protein*Journal of Clinical Endocrinology & Metabolism, 1988
- Diurnal Rhythm of Growth Hormone-Independent Binding Protein for Insulin-like Growth Factors in Human Plasma*Journal of Clinical Endocrinology & Metabolism, 1987
- Placental Protein 12 Is a Decidual Protein that Binds Somatomedin and Has an Identical N-Terminal Amino Acid Sequence with Sdmatomedin-Binding Protein from Human Amhiotic Fluid*Endocrinology, 1986
- Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluidActa Endocrinologica, 1984
- Immunoassay of a Somatomedin-Binding Protein from Human Amniotic Fluid: Levels in Fetal, Neonatal, and Adult Sera*Journal of Clinical Endocrinology & Metabolism, 1984
- Isolation and characterization of a somatomedin‐binding protein from mid‐term human amniotic fluidEuropean Journal of Biochemistry, 1984
- Plasma Somatomedin-Binding Proteins in Hypopituitarism: Changes during Growth Hormone Therapy*Journal of Clinical Endocrinology & Metabolism, 1981